Fagron NV (EBR:FAGR)
Belgium
· Delayed Price · Currency is EUR 19.24
-0.14 (-0.72%)
Feb 21, 2025, 5:35 PM CET
Fagron NV Revenue
In the year 2024, Fagron NV had annual revenue of 874.84M EUR with 14.66% growth. Fagron NV had revenue of 429.34M in the half year ending June 30, 2024, with 30.67% growth.
Revenue
874.84M
Revenue Growth
+14.66%
P/S Ratio
1.61
Revenue / Employee
239.88K
Employees
3,282
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 874.84M | 111.85M | 14.66% |
| Dec 31, 2023 | 762.99M | 79.11M | 11.57% |
| Dec 31, 2022 | 683.88M | 110.07M | 19.18% |
| Dec 31, 2021 | 573.81M | 17.84M | 3.21% |
| Dec 31, 2020 | 555.97M | 21.28M | 3.98% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| argenx SE | 1.71B |
| UCB SA | 5.45B |
| Ion Beam Applications | 465.75M |
| Nyxoah | 5.08M |
| Onward Medical | -188.00K |
| Hyloris Pharmaceuticals | 6.94M |
| Sequana Medical NV | 433.50K |
| Biocartis Group NV | 60.82M |
Fagron NV News
- 6 weeks ago - Fagron: FDA Warning Letter Creates New Entry Opportunity - Seeking Alpha
- 4 months ago - Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook - GlobeNewsWire
- 11 months ago - Record revenue of €209 million in first quarter reflecting 15% topline growth - GlobeNewsWire
- 1 year ago - Continued strong third quarter performance with 11% topline growth to €191 million - GlobeNewsWire
- 1 year ago - Fagron NV (ARSUF) Q2 2023 Earnings Call Transcript - Seeking Alpha